Cecilia Leijding

Cecilia Leijding

Auto-generated profile, based on publicly available information

Cecilia Leijding

Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2026 in Journal of Autoimmunity
Verified
Journal Article
Open access
CLCecilia Leijding
Cecilia Leijding
SGStefano Gastaldello
Stefano Gastaldello
TSTomas Schiffer
Tomas Schiffer
SKSuchada Kaewin
Suchada Kaewin
KAKristofer M. Andreasson
Kristofer M. Andreasson
DADaniel C Andersson
Daniel C Andersson
Idiopathic inflammatory myopathies (IIM) are systemic autoimmune disorders characterized by skeletal muscle weakness and inflammatory cell infiltrates in muscle tissue. Although circulating systemic factors have been implicated in IIM, it is unclear to what extent such factors shape the muscle disease phenotype. Using a model that can isolate the effect of serum from other systemic influences, we aimed to investigate how serum from IIM affects skeletal muscle contractility, mitochondrial function and inflammatory signalling. Isolated skeletal muscles (m. flexor digitorum brevis) from C57BL/6JRj mice were exposed for 24 h to sera from patients with IIM (n = 11) or healthy control sera. Muscle force was measured before and after serum exposure to assess weakness. Gene and protein expression was analysed to assess mitochondrial biogenesis and inflammatory cytokines. Mitochondrial respiration was assessed by high-resolution respirometry. Muscle transcriptomics was performed to identify signalling pathways perturbed by the IIM sera. Muscles exposed to sera from patients with IIM displayed significant contractile weakness and impaired mitochondrial respiratory capacity compared to muscles exposed to control sera (complex I; p = 0.0004, complex II; p = 0.0254, maximal electron transport chain activity; p = 0.0012). IIM sera induced upregulation of TNF-α (p = <0.0001) and IL1β (p = 0.0002) in the isolated muscles. Transcriptomics revealed significant enrichment in pathways linked to inflammation, mitochondrial metabolism and cytokine activity. Serum from patients with IIM induced disease relevant phenotypes like those observed in muscle of patients, including weakness, local cytokine expression and mitochondrial dysfunction. These findings support the relevance of our model in recapitulating key features of IIM and further the mechanistic insights.

28 August 2024 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
CLCecilia Leijding
Cecilia Leijding
SKSuchada Kaewin
Suchada Kaewin
KAKristofer M Andreasson
Kristofer M Andreasson
BHBegum Horuluoglu
Begum Horuluoglu
AGAngeles Shunashy Galindo-Feria
Angeles Shunashy Galindo-Feria
DADaniel C Andersson
Daniel C Andersson

27 November 2025 in EBioMedicine
Verified
Journal Article
Open access
KAKristofer M. Andreasson
Kristofer M. Andreasson
CLCecilia Leijding
Cecilia Leijding
MDMaryam Dastmalchi
Maryam Dastmalchi
ANAntonella Notarnicola
Antonella Notarnicola
SGStefano Gastaldello
Stefano Gastaldello
HAHelene Alexanderson
Helene Alexanderson
To investigate efficacy, safety, and tolerance of high-intensity interval training (HIIT) vs. clinical standard low-moderate intensity home-based exercise (CON) to improve aerobic capacity, muscle endurance, and mitochondrial function in patients with recent onset, idiopathic inflammatory myopathies (IIM). Twenty-three patients with recent onset IIM were randomised into HIIT or CON groups. Both groups underwent 12 weeks of exercise training. The HIIT did 3 sessions/week, always supervised during the first three weeks. Then, training was supervised 1-3 session per week based on an individual assessment of the participants' preference and ability to perform HIIT in the clinic. The CON received one supervised session and then exercised five days per week at home, following clinical standard. Primary outcome was maximal exercise test (VO2peak l/min and ml/kg x min, peak power (Watt), time-to-exhaustion TTE min/sec), with secondary outcomes mitochondrial protein expression in muscle. Safety was assessed by disease activity (serum levels of muscle enzymes, muscle strength (MMT8), Physician Global Assessment, pain, and fatigue (VAS, 0-100). HIIT resulted in a 16% increase in VO2peak L/min, significantly higher than the 1.8% change in CON (95% CI 0.1; 0.47). Peak power and TTE improved significantly more in HIIT, 18% and 23%, respectively, compared to CON, 8% and 12% (95% CI 3.9; 30.8 and 00:06; 03:18, respectively). Muscle biopsies (HIIT n = 7, CON n = 6) showed increases (p < 0.05) in central mitochondrial protein expression in HIIT but not CON, suggesting enhanced mitochondrial function. Both groups maintained stable serum muscle enzymes indicating no increase in disease activity from the intervention. Muscle disease activity remained low and unchanged in both groups (95% CI -1.2; 1.0), physician global activity and MMT8 significantly improved within CON (95% CI -1.7; -0.26 and 0.1; 3.9, respectively) but not in the HIIT group. HIIT is an effective and safe exercise intervention to improve aerobic fitness, muscle endurance, and mitochondrial function in patients with recent onset IIM. This approach should be considered an adjuvant treatment in managing IIM, potentially health-enhancing for these patients. Swedish Research Council, the Swedish Rheumatism Association, Stockholm County Research Grant (ALF), King Gustaf V 80-year Foundation, the Swedish Heart and Lung Foundation, Promobilia Foundation, and Stig Thune Foundation.

17 March 2026 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
SKSuchada Kaewin
Suchada Kaewin
CLCecilia Leijding
Cecilia Leijding
SGStefano Gastaldello
Stefano Gastaldello
DMDavid Makari
David Makari
YZYi Zhong
Yi Zhong
DADaniel C Andersson
Daniel C Andersson
Dermatomyositis (DM) is characterised by systemic inflammation, debilitating muscle weakness, cutaneous lesions, and increased mortality. An upregulation of type I interferon (IFN)-stimulated genes is observed in patients with DM. However, it remains unclear whether type I IFNs cause muscle weakness in DM. This study aimed to investigate the role of IFN-α/β receptor signalling in muscle weakness induced by factors in DM serum. In ex vivo experiments, flexor digitorum brevis muscles were isolated from healthy mice and incubated 24 hours with 10% healthy serum or serum from patients with DM (n = 9). To modulate IFN signalling, an antibody against the type I IFN receptor α/β subunit 1 (IFNAR1) or the Janus kinase-signal transducer and activator of transcription inhibitor ruxolitinib was used. RNA sequencing, followed by bioinformatics analysis, was conducted to identify differentially expressed genes and affected pathways related to IFN signalling. Incubation with serum from patients with DM, but not that from healthy controls, caused significant muscle weakness manifested by a reduction in muscle force. Bioinformatic analyses revealed downregulation of type I IFN-inducible genes with IFNAR1 antibody. Pathway analysis showed enrichment of several IFN-related pathways. Inhibition of type I IFN signalling with either an IFNAR1 antibody or ruxolitinib abolished DM serum-induced effects. Factors in serum from patients with DM can activate the type I IFN signalling pathway in skeletal muscles, which constitutes an important causal factor for muscle weakness. Our data support a mechanistic model where blood-borne factors contribute to muscle disease phenotypes and underscore the therapeutic possibilities of pharmacological interventions targeting the IFNAR1 signalling pathway.

8 December 2024 in medRxiv
Verified
Preprint
Open access
PDF file
KAKristofer M. Andreasson
Kristofer M. Andreasson
CLCecilia Leijding
Cecilia Leijding
MDMaryam Dastmalchi
Maryam Dastmalchi
ANAntonella Notarnicola
Antonella Notarnicola
SGStefano Gastaldello
Stefano Gastaldello
HAHelene Alexanderson
Helene Alexanderson
Objective: To investigate efficacy, safety, and tolerance of high-intensity interval training (HIIT) versus standard low-moderate intensity home-based exercise (CON) to improve aerobic capacity, muscle endurance, and mitochondrial function in patients with recent onset, idiopathic inflammatory myopathies (IIM). Methods: Twenty-three patients with recent onset IIM were randomized into two groups: HIIT and CON. HIIT underwent 12 weeks of supervised high-intensity training, while CON followed a low-moderate intensity home-based exercise program. Outcomes included maximal exercise test (VO 2 peak, peak power, time-to-exhaustion (TTE)), mitochondrial protein expression in muscle biopsy serum levels of muscle enzymes (CK, LD, AST, ALT), muscle strength (MMT8) and disease activity (subset of MDAAT), before and after intervention. Results: HIIT resulted in a 16 % increase in VO 2 peak L/min, significantly higher than the 1.8 % change in CON (95 % CI 0.1;0.47). Peak power and TTE also improved significantly more in HIIT, 18 % and 23 %, respectively, compared to CON, 8 % and 12 %, (95 % CI 3.9;30.8 and 00:06;03:18, respectively). Muscle biopsies (HIIT n=7, CON n=6) showed increases (p<0.05) in central mitochondrial protein expression in HIIT but not in CON, suggesting enhanced mitochondrial function. Both groups maintained stable serum muscle enzymes indicating no increase in disease activity from the intervention. Muscle disease activity remained low and unchanged in both groups (95 % CI −1.2;1.0), physician global activity and MMT8significantly improved within CON (95 % CI −1.7;-0.26 and 0.1;3.9, respectively) but not in the HIIT group. Compliance with HIIT was high, and no adverse events were reported. Conclusion: HIIT is a highly effective and safe exercise intervention to improve aerobic fitness, muscle endurance, and mitochondrial function in patients with recent onset IIM. This approach should be considered as an adjuvant treatment in managing IIM, potentially enhancing the health for these patients. The study was registered at ClinicalTrials.gov : NCT03324152 Significance and Innovations: High-intensity interval training (HIIT) is more effective to improve aerobic capacity (peak oxygen uptake; VO 2 peak), increasing 16 % compared to 1.8 % change in the moderate exercise control group in patients with recent onset IIM. HIIT produced larger exercise adaptations with increased expression of aerobic metabolism (mitochondrial) proteins in muscle tissue compared to moderate exercise. HIIT is a safe and well tolerated exercise intervention for patients with recent onset IIM.

15 January 2020 in The Journal of Physiology
Verified
Journal Article
Closed access
PDF file
SMSarah Mosely
Sarah Mosely
CLCecilia Landberg
Cecilia Landberg